SAILIFEPharmaceuticals
Sai Life Sciences Ltd — Cash Flow Statement
₹972.00
-1.32%
Sai Life Sciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Free Cash Flow | -55.23 Cr | 81.40 Cr | 106.33 Cr | -102.05 Cr |
| Repayment Of Debt | -389.87 Cr | -66.73 Cr | -53.28 Cr | -31.63 Cr |
| Issuance Of Debt | 53.41 Cr | 75.00 Cr | 30.00 Cr | 100.15 Cr |
| Issuance Of Capital Stock | 1.01K Cr | 0.97 Cr | 2.09 Cr | 3.13 Cr |
| Capital Expenditure | -369.28 Cr | -181.69 Cr | -113.08 Cr | -206.91 Cr |
| End Cash Position | 91.05 Cr | 11.97 Cr | 35.53 Cr | 115.78 Cr |
| Beginning Cash Position | 11.97 Cr | 35.53 Cr | 115.78 Cr | 40.63 Cr |
| Effect Of Exchange Rate Changes | 0.28 Cr | 1.03 Cr | 2.78 Cr | 2.08 Cr |
| Changes In Cash | 78.81 Cr | -24.59 Cr | -83.03 Cr | 73.08 Cr |
| Financing Cash Flow | 301.43 Cr | -95.30 Cr | -200.65 Cr | 71.92 Cr |
| Interest Paid Cff | -77.41 Cr | -85.33 Cr | -78.50 Cr | -50.07 Cr |
| Net Common Stock Issuance | 1.01K Cr | 0.97 Cr | 2.09 Cr | 3.13 Cr |
| Common Stock Issuance | 1.01K Cr | 0.97 Cr | 2.09 Cr | 3.13 Cr |
| Net Issuance Payments Of Debt | -570.42 Cr | 33.16 Cr | -89.71 Cr | 142.46 Cr |
| Net Short Term Debt Issuance | -233.96 Cr | 24.89 Cr | -66.44 Cr | 73.94 Cr |
| Net Long Term Debt Issuance | -336.46 Cr | 8.27 Cr | -23.28 Cr | 68.52 Cr |
| Long Term Debt Payments | -389.87 Cr | -66.73 Cr | -53.28 Cr | -31.63 Cr |
| Long Term Debt Issuance | 53.41 Cr | 75.00 Cr | 30.00 Cr | 100.15 Cr |
| Investing Cash Flow | -536.66 Cr | -192.38 Cr | -101.78 Cr | -103.71 Cr |
| Interest Received Cfi | 15.91 Cr | 12.18 Cr | 8.31 Cr | 8.85 Cr |
| Net Investment Purchase And Sale | -183.70 Cr | -23.72 Cr | -2.07 Cr | -4.69 Cr |
| Net Business Purchase And Sale | -0.07 Cr | 0.00 | -1.85 Cr | 0.00 |
| Purchase Of Business | -0.07 Cr | 0.00 | -1.85 Cr | 0.00 |
| Net PPE Purchase And Sale | -368.80 Cr | -180.84 Cr | -71.17 Cr | -108.37 Cr |
| Sale Of PPE | 0.48 Cr | 0.85 Cr | 41.91 Cr | 98.54 Cr |
| Purchase Of PPE | -369.28 Cr | -181.69 Cr | -113.08 Cr | -206.91 Cr |
| Operating Cash Flow | 314.05 Cr | 263.09 Cr | 219.40 Cr | 104.87 Cr |
| Taxes Refund Paid | -21.63 Cr | -13.87 Cr | -4.08 Cr | -8.12 Cr |
| Change In Working Capital | -131.09 Cr | -38.24 Cr | 34.93 Cr | -24.55 Cr |
| Change In Other Current Liabilities | 47.77 Cr | 43.51 Cr | 17.41 Cr | -4.50 Cr |
| Change In Other Current Assets | -153.35 Cr | -92.60 Cr | 62.83 Cr | 9.46 Cr |
| Change In Payable | 105.88 Cr | -70.05 Cr | 12.38 Cr | 64.30 Cr |
| Change In Inventory | -31.42 Cr | 52.09 Cr | -12.62 Cr | -50.56 Cr |
| Change In Receivables | -99.97 Cr | 28.81 Cr | -45.08 Cr | -43.24 Cr |
| Other Non Cash Items | 58.60 Cr | 72.31 Cr | 66.39 Cr | 42.52 Cr |
| Stock Based Compensation | 2.48 Cr | 2.25 Cr | 0.81 Cr | 2.24 Cr |
| Provisionand Write Offof Assets | 0.00 | 1.37 Cr | 1.15 Cr | 5.37 Cr |
| Depreciation And Amortization | 138.57 Cr | 119.44 Cr | 99.43 Cr | 90.16 Cr |
| Depreciation | 138.57 Cr | 119.44 Cr | 94.86 Cr | 86.92 Cr |
| Net Foreign Currency Exchange Gain Loss | 4.97 Cr | -4.44 Cr | -3.00 Cr | -1.88 Cr |
| Gain Loss On Sale Of PPE | 1.81 Cr | -0.01 Cr | 0.57 Cr | -11.31 Cr |
| Net Income From Continuing Operations | 227.70 Cr | 109.23 Cr | 16.41 Cr | 9.70 Cr |
| Net Other Investing Changes | — | 95.00 Cr | -35.00 Cr | 0.50 Cr |
| Purchase Of Investment | — | -118.72 Cr | -2.07 Cr | -4.69 Cr |
| Amortization Cash Flow | — | 8.77 Cr | 4.57 Cr | 3.24 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sai Life Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.